A Study Aiming to Demonstrate That the Addition of Intravenous (IV) Tranexamic Acid-Compared to Placebo-During Anterior Cruciate Ligament (ACL) Reconstruction Results in Reduced Blood Loss and Postoperative Pain.

Inclusion Criteria: * Male or female patient aged over 18 years4 * Patient with a surgical indication for primary reconstruction of an isolated ACL, +/- requiring an anterolateral reconstruction procedure or meniscectomy/meniscal repair * Planned outpatient surgical procedure * Patient affiliated with or a beneficiary of a social security scheme * Patient informed about the study and having signed the informed consent form Exclusion Criteria: * Patient with a history of ACL surgery * Patient with a history of knee surgery other than meniscectomy * Patient with multi-ligament knee injuries (PCL, MCL, or LCL) * Patient with a contraindication to the use of tranexamic acid: Hypersensitivity to the active substance or any of the excipients, acute venous or arterial thrombosis, fibrinolytic states resulting from consumptive coagulopathy (except in states associated with predominant activation of the fibrinolytic system with acute severe hemorrhage), severe renal impairment (risk of accumulation), history of convulsions, intrathecal and intraventricular injections, intracerebral applications (risk of cerebral edema and convulsions) * Patient with a hemostatic disorder, undergoing treatment with VKAs or anticoagulants, or receiving hormone replacement therapy * Patient with hepatic impairment * Patient with renal impairment * Patient unable or not in a position to agree to the entire procedure and follow-up required by the study * Patient participating in another clinical study * Protected patient: adult under guardianship, curatorship, or other legal protection; deprived of liberty by judicial or administrative decision * Pregnant or breastfeeding woman * Patient hospitalized without consent